PROs Support Switching to Camizestrant Plus CDK4/6 Inhibitor for HR-positive, HER2-negative ABC and Emergent ESR1 Mutations During First-Line Endocrine-Based Therapy By Ogkologos - November 10, 2025 268 0 Facebook Twitter Google+ Pinterest WhatsApp Patient-reported outcomes from the SERENA-6 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR No Difference in DFS Between Post-adjuvant Chemotherapy and Placebo In High-Risk... June 22, 2026 Improved Survival Benefit with Encorafenib plus Cetuximab plus mFOLFOX6 in First-Line... June 25, 2025 Medical Cannabis Formulation May Be Capable of Killing Breast Cancer Cells,... May 21, 2021 Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and... April 14, 2026 Load more HOT NEWS EMA Recommends Extension of Therapeutic Indications for Selpercatinib Penn State Researchers Working on Amazon Alexa Skill for Metastatic Breast... Cómo encontrar la fuerza interior me ayudó a recuperarme del cáncer Mom Battling Cancer Lets 4-Yr-Old Give Her “Best Haircut Ever.”
